Mayank's Profound AI Rep
Mayank's view on early-stage investing shows how he thinks about founder coachability over financial models.
Mayank Srivastava
Edges
Running Startup Evaluation End to End
Mayank owns the full research cycle on early-stage startups: from gathering the initial brief and pitch materials through market sizing, founder assessment, financial analysis, valuation, and IC memo preparation. This pattern has shown up at BIORx Ventures, where he took a healthcare technology startup from initial brief through to a structured investment committee presentation, and at Prasuta Ventures, where he built a DCF valuation report independently from scratch. His framework is consistent: understand the business and market first, then evaluate the founder, product, customers, and financials before landing on a valuation and a clear recommendation. He does not skip layers. For an early-stage analyst, the ability to hold the full arc of an evaluation without losing structure is the core skill this edge reflects.
Spotted in 2 Stories
P
Healthcare Technology Sector Lens
Mayank has built a working view on healthcare technology independently, shaped by deal exposure at BIORx and his own reading and research. His view centers on the intersection of AI and healthcare delivery: diagnostics, cost reduction, access, and scalable business models with clinical validation. He has evaluated healthcare technology startups at BIORx, including an AI-powered solution in the diagnostics space, and has developed a clear framework for what separates viable healthcare startups from those that will struggle with regulatory cycles and adoption. His sector view is not just analytical. He tracks the space actively, follows regulatory developments, and understands the unit economics challenges specific to healthcare, including approval timelines and customer adoption curves. For a research role covering frontier and technology sectors, this is a formed view, not a surface-level interest.
Spotted in 2 Stories
Startup Valuation and Financial Modeling
Mayank builds financial models and valuation analyses for early-stage startups, selecting the right methodology based on the company's stage and available data. His toolkit includes DCF, comparable company analysis, comparable transactions, and the VC method. At BIORx, he performed full valuation analyses as part of IC memo preparation for healthcare technology startups. At Prasuta Ventures, he built a DCF model from scratch, including the thesis and workbook, earning strong feedback from the leadership team on his assumptions and structure. His approach to valuation at the early stage is grounded in the reality that financial data is often limited. He benchmarks against comparable companies, stress-tests assumptions, and is explicit about the risks embedded in his estimates. For a research role where valuation is a core deliverable, this is a practiced skill with real output behind it.
Spotted in 2 Stories
PMayank Srivastava
About Me
Mayank Srivastava is a financial analyst and startup evaluator with experience spanning investment banking, venture advisory, and business development. He works across healthcare technology, Consumer brands edtech, with a focus on early-stage startup analysis and structured investment recommendations.
Currently at BIORx Ventures as an Investment Banking Analyst and Assistant Manager, he owns the full research cycle: from founder assessment and market sizing to financial modeling, valuation, and IC memo preparation.
At Prasuta Ventures, he drafted DCF-based valuation reports from scratch, receiving strong feedback from the leadership team on his analysis structure and assumptions.
Earlier at DMS IT Consulting, he managed a pipeline of 50+ new clients per quarter and negotiated contracts on deals above $50K, building his foundation in client relationships and business communication.
Mayank Srivastava
At the early stage, you're not analyzing a business. You're betting on whether a founder can build one.”
Mayank Srivastava
On early-stage investing